Adherence to preexposure chemoprophylaxis: The behavioral bridge from efficacy to effectiveness

Current Opinion in HIV and AIDS

Volumn 7, Issue 6, 2012, Pages 542-548

  Amico, K Rivet ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

adherence; bio behavioral; PrEP; review

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ORAL CONTRACEPTIVE AGENT; WARFARIN;

ANTIVIRAL THERAPY; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK MANAGEMENT; SELF REPORT; TOPICAL TREATMENT;

ANTI-HIV AGENTS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE;

EID: 84868455990     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283582d4a     Document Type: Review

References (49)

1. Grant RM, Lama JR, Anderson PL, et al. Completed observation of the randomized placebo-controlled phase of iPrEx: daily oral FTC/TDF preexposure HIV prophylaxis among men and trans women who have sex with men. Sixth IAS Conference, Rome, abstract WELBC04, 2011. http://pag.ias 2011.org/PAGMaterial/ IAS2011/PPT/598-642/grant%20et%20al%20 completed%20observation%20final%204.pptx
2. Anderson PL, Lama JR, Buchbinder S, et al. Expanded case-control analysis of drug detection in the global iPrEx trial. Sixth IAS Conference, Rome, abstract MOLBPE034; 2011.
3. Van Damme L, Corneli A, Ahmed K, et al.; the FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012. [Epub ahead of print]
4. Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep 2011; 8:94-103.
5. Leibowitz AA, Parker KB, Rotheram-Borus MJ. A US policy perspective on oral preexposure prophylaxis for HIV. AJPH 2011; 101:982-985.
6. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk US populations: current considerations in light of new findings. Aids Patient Care STDs 2011; 25:63-71.
7. Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep 2008; 5:186-192.
8. Amico KR, Liu A, McMahan V, et al. Adherence indicators and preexposure prophylaxis (PrEP) drug levels in the iPrEx study. 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, US; 2011.
9. Anderson PL, Lama JR, Buchbinder S, et al. Interpreting detection rates of intracellular emtricitabine-triphosphate (FTC-TP) and tenofovir-diphosphate (TFV-DP) in the iPrEx trial. 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, US; 2011.
10. Anderson P, Liu A, Buchbinder S, et al. Intracellular tenofovir-DP concentrations associated with PrEP efficacy in MSM from iPrEx. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March
11. Seattle. Abstract 31LB. http://retroconference.org/static/webcasts/2012/
12. Baeten JM, Donnell D, Ndase P, et al.; the Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012. [Epub ahead of print]
13. Donnell D, Baeten J, C Hendrix C, et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012. Seattle. Abstract 30.
14. Grant RM, Lama JR, Anderson PL, et al., for the iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010. doi: 10.1056/NEJMoa1011205.
15. Grant R, Lama J, Glidden D, et al. Preexposure chemoprophylaxis for prevention of HIV among trans-women and MSM: iPREx Study. 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, US; 2011.
16. Wei X, Morris L, Naranbhai V, et al. Sensitive tenofovir resistance screening of HIV-1 from the genital tract of women with breakthrough infections in the CAPRISA 004 Tenofovir gel trial. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012. Seattle. Abstract 33.
17. Kashuba AD, Abdool Karim SS, Kraft E, et al. Do systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial? Oral abstract TUSS0503. AIDS 2010, Vienna 18-23 XVIII International AIDS Conference.
18. Thigpen MC, Kebaabetswa PM, Paxton L, et al.; for the TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. NEJM 2012. (10.1056/NEJMoa1110711)
19. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
20. Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav 2012 [Epub ahead of print] PMID: 22407465.
21. Mutua G, Sanders E, Mugo P, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS ONE 2012; 7:e33103.
22. Ware NC, Wyatt MA, Haberer JE, et al. What's love got to do with it? Explaining adherence to oral antiretroviral preexposure prophylaxis for HIVserodiscordant couples. J Acquir Immune Defic Syndr 2012; 59:463-468.
23. Amico KR, Marcus JL, McMahan V, et al. Correlates of study product use among U.S. participants in the iPrEx randomized controlled trial of daily oral preexposure prophylaxis. July 2012. International AIDS Conference (AIDS 2012). Washington DC.
24. Haberer J, Baeten J, Celum C, et al. Near perfect early adherence to antiretroviral preexposure prophylaxis (PrEP) against HIV infection among HIV-serodiscordant couples as determined by multiple measures: preliminary data from the Partners PrEP study. Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston. Abstract 488; 2011.
25. Roberts ET, Matthews DD. HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention. Soc Sci Med 2012. doi: 10.1016/j.socscimed.2012.02.016.
26. Amico KR. Standard of care for antiretroviral therapy adherence and retention in care from the perspective of care providers attending the 5th International HIV Treatment Adherence Conference. J Int Assoc Phys AIDS Care 2011; 10:291-296.
27. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. JAIDS 2006; 41:285-297.
28. Simoni JM, Pearson CR, Pantalone DW, et al. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load: a meta-analytic review of randomized controlled trials. JAIDS 2006; 43:S23-S35.
29. Centers for Disease Control and Prevention. Compendium of evidencebased HIV behavioral interventions: medication adherence chapter. Available at: http://www.cdc.gov/hiv/topics/research/prs/ma-chapter.htm Accessed September 25 2011.
30. Wilson IR, Carter AE, Berg KM. Improving the self-report of HIV antiretroviral medication adherence: Is the glass half full or half empty? Curr HIV/AIDS Rep 2009; 6:177-186.
31. Ortego C, Huedo-Medine TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav 2011; 15: 1381-1396.
32. Hou M, Hurwitz S, Kavanagh E, et al. Using daily text-message reminders to improve adherence with oral contraceptives: a randomized controlled trial. Obstet Gynecol 2010; 116:633-640.
33. Armstrong AW, Watson AJ, Makredes M, et al. Text-message reminders to improve sunscreen use: a randomized, controlled trial using electronic monitoring text-message reminders to improve sunscreen use. Arch Dermatol 2009; 145:1230-1236.
34. Fumaz CR, Munoz-Moreno J, Molto J, et al. Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: attitudes and beliefs. AIDS Care 2008; 20:796-805.
35. Parker CS, Chen Z, Price M, et al. Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med 2007; 22:1254-1259. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219760/. Accessed May 16, 2012.
36. Centers for Disease Control and Prevention. Morbidity and mortality weekly report (MMWR), Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. 2011; 60:65-68. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm?s-cid=mm 6003a1-w Accessed September 25 2011.
37. Van der Straten A, van Damme L, Haberer JE, Bangsberg DR. How well does PrEP work? Unraveling the divergent results of PrEP trials for HIV prevention. AIDS 2012; 26 [Epub ahead of print].
38. Liu A, Colfax G, Cohen S, et al. The spectrum of engagement in HIV prevention: proposal for a PrEP cascade [80040]. Presented at the 7th Annual HIV Treatment and Prevention Adherence Conference of the International Association of Providers in AIDS Care, Miami, FL; 2012.
39. Amico KR, McMahan V, Marcus J, et al. Integrated next step counseling (iNSC): a discussion based sexual health promotion conversation to support men who have sex with men using PrEP in the iPrEx open label extension [80467]. Oral presentation at the 7th Annual HIV Treatment and Prevention Adherence Conference of the International Association of Providers in AIDS Care, Miami, FL; 2012.
40. Amico KR, McMahan V, Goicochea P, et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Beh 2012 [Epub ahead of print].
41. Ferrer RA, Morrow KM, Fisher WA, Fisher JD. Toward an informationmotivation- behavioral skills model of microbicide adherence in clinical trials. AIDS Care 2010; 22:997-1005.
42. Munro S, Lewin S, Swart T, Volmink J. A review of health behaviour theories: how useful are these for developing interventions to promote long-term medication adherence for TB and HIV/AIDS? BMC Public Health 2007; 7:104.
43. Amico KR. Behavioral threats to PrEP success. Presented at the TasP PrEP evidence summit 2012 (International Association of Physicians in AIDS Care and British HIV Association). London, UK. June 11-12 2012.
44. Spire B, Molina JM, Aboulker JP, Le Gall JM. Preexposure prophylaxis in France. IPERGAY. Presented at the TasP PrEP evidence summit 2012 (International Association of Physicians in AIDS Care and British HIV Association). London, UK. June 11-12 2012.
45. HIV Prevention Trials Network. HPTN 067: The ADAPT Study. 2012. Accessed June 15th 2012 from http://www.hptn.org/research-studies/hptn067.asp
46. Follow-on African Consortium for Tenofovir Studies (FACTS) Consortium. FACTS 001. 2012. Accessed June 1st 2012 from http://www.factsconsortium. co.za/
47. Vaginal and Oral Interventions to Control the Epidemic (VOICE). Microbicide Trials Network. 2012. Accessed June 1st 2012 from http://www.mtnstopshiv. org/news/studies/mtn003
48. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care Panel. Ann Intern Med 2012 [Epub ahead of print] PMID: 22393036.
49. Marcus J, Amico KR, Golub S, et al. Potential interventions to support adherence to HIV preexposure prophylaxis: a systematic review. Poster 79997 at the 7th Annual HIV Treatment and Prevention Adherence Conference of the International Association of Providers in AIDS Care, Miami, FL; 2012.